Navigation Links
QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
Date:12/15/2008

ficacy relating to the time to onset of analgesia and global assessment of effect; and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

MoxDuoIR(TM) is a patented combination of morphine and oxycodone which has been clinically shown to provide synergistic effects on pain relief, resulting in a significant reduction of total opioid dose and side effects.

Based on the Company's July 2008 FDA meeting, final Phase 3 studies for MoxDuoIR(TM) will include a combination rule trial in patients experiencing post-surgery (bunionectomy) pain. Data collected from the comparative study will be used to select the optimal dose regimen and sample sizes for the combination rule trial. No additional pharmacology, toxicology or long-term clinical safety studies will be required for regulatory submission and market approval.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Compan
'/>"/>

SOURCE QRxPharma Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
3. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
4. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
5. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
11. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DIEGO and SHENZHEN, China ... announced today the purchase of an Irys™System ... organization. BGI selected BioNano,s platform to enable comprehensive exploration ... improved assemblies for various organisms of interest, including those ... will partner together to develop new methods for multiplexing ...
(Date:7/31/2014)... 31, 2014 Although RNA-Sequencing is ... first transcriptome-wide analyses appearing around 2008, RNA-Sequencing has ... RNA measurement. In the last several years, assays ... work with smaller input amounts, process degraded RNA, ... samples). On the bioinformatics side, there have been ...
(Date:7/31/2014)... Miami, Fla. (PRWEB) July 31, 2014 The ... for distribution of its monthly news magazine, Kidney Cancer News. ... have a presence on a website maintained by an international ... noted an immediate increase in viewers.” , This month’s program ... of kidney tumors analyzed in a recent study. Kidney ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
Breaking Biology Technology:BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... as a 2010 American Chemical Society Fellowa distinguished group of ... or industry. Donna Nelson, professor in the OU Department ... ceremony at the ACS National Meeting in Boston on August ... second group of chemists to be honored for contributions to ...
... toward understanding the unique and often unexpected properties of ... because of its potential applications in future generations of ... edition of the journal Nature Physics , researchers ... Institute of Standards and Technology (NIST) describe for the ...
... State University have demonstrated the first plastic computer memory ... and write data. An alternative to traditional microelectronics, ... process data faster, and consume less power. In ... Materials , Arthur J. Epstein and colleagues describe how ...
Cached Biology Technology:Study of electron orbits in multilayer graphene finds unexpected energy gaps 2Study of electron orbits in multilayer graphene finds unexpected energy gaps 3Study of electron orbits in multilayer graphene finds unexpected energy gaps 4Researchers successfully test new alternative to traditional semiconductors 2Researchers successfully test new alternative to traditional semiconductors 3
(Date:7/31/2014)... Dr. Oren Tessler, Assistant Professor of Clinical Surgery ... Medicine, is part of a team of plastic and ... a method to screen and select patients for a ... the patients who underwent this surgery to decompress the ... a bonus cosmetic eyelid surgery. The study, which confirms ...
(Date:7/31/2014)... 31, 2014 Biometrics industry sees ... smart technologies; companies turn towards digital currency: NXT-ID, Inc. ... Amazon.com Inc. (NASDAQ: AMZN ), Facebook Inc. ... GOOG ) and Microsoft Corporation (NASDAQ: MSFT) ... the growing m-commerce market, announces a video featuring its ...
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Engineering a protein to prevent brain damage from toxic agents 2
... research at Rutgers University may help shed light on how ... people to suffer from life-threatening anxiety disorders while others are ... the Department of Genetics, and a team of researchers, found ... in the roundworm, responsible for receiving information, undergo major changes ...
... often recall their dreams respond more strongly to their name ... of human cognition. It is still not fully known when ... A major difficulty for studying dreams is that they leave ... and colleagues from the Lyon Neuroscience Research Center chose a ...
... and climate events like storms, heavy precipitation and droughts and ... by the global vegetation. A team of scientists under the ... for Biogeochemistry in Jena, Germany, investigated the effect of extremes ... the first time. In the current issue of Nature ...
Cached Biology News:Rutgers study: Worms may shed light on human ability to handle chronic stress 2Frontiers news briefs: Aug. 13 2Frontiers news briefs: Aug. 13 3Extreme weather, climate and the carbon cycle 2
Request Info...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
...
Normal human AB serum, pooled...
Biology Products: